摘要
目的检测恶性肿瘤患者UGT1A1*28基因多态性的分布情况,探讨其与伊立替康所致不良反应的关系。方法对63例恶性肿瘤外周血标本采用PCR扩增和基因测序的方法检测UGT1A1*28的基因型TA(6)/TA(6)纯合子、TA(6)/TA(7)杂合子、TA(7)/TA(7)纯合子。结果迟发性腹泻的发生上一般临床特征如患者的年龄、性别、ECOG评分、复发转移灶、合并疾病史、剂量强度差异均无统计学意义(P>0.05);而在中性粒细胞减少的发生上,剂量强度是危险因素(P<0.05),余各项特征差异无统计学意义(P>0.05);TA(6)/TA(6)正常野生型48例(76.19%),TA(6)/TA(7)杂合基因型15例(23.81%),TA(7)/TA(7)纯合突变型0例;基因TA(6)/TA(6)野生型与TA(6)/TA(7)杂合型在患者的性别、年龄、ECOG评分、合并疾病、原发灶的部位与复发转移灶临床特征之间差异均无统计学意义(P>0.05)。结论 UGT1A1*28基因TA(6)/TA(6)野生型最为常见,TA(6)/TA(7)杂合型次之;迟发性腹泻的发生与剂量强度无明显相关性,UGT1A1*28基因多态性是腹泻危险因素,TA(6)/TA(7)型基因患者迟发性腹泻的发生率增加;中性粒细胞减少的发生与剂量强度呈正相关,剂量强度越大的患者可能越易发生中性粒细胞的减少。
Objective To detect UGT1A1＊28gene polymorphism in patients with malignant tumor and explore its relationship between UGT1A1＊28gene polymorphism and irinotecan-induced adverse reactions.Method 63 cases of malignant tumors were detected by PCR amplification and sequencing of UGT1A1＊28gene,including homozygous TA（6）/TA（6）,heterozygotes TA（6）/TA（7）,homozygous TA（7）/TA（7）.Result General clinical features in delayed diarrhea occurred such as age,gender,ECOG score,recurrence transfer stove,merged disease history,and dose strength that there were no statistical significantly differences（P〈0.05）.And dose strength was dangerous factors（P〈0.05）in neutropenia occurred,other the features that there were no statistical significantly differences（P〈0.05）.Normal wild type TA（6）/TA（6）was 48cases（76.19%）,miscellaneous collection gene type TA（6）/TA（7）was 15cases（23.81%）,that do not have homozygous mutant TA（7）/TA（7）.Wild type TA（6）/TA（6）and heterozygous TA（6）/TA（7）in gender,age,concomitant diseases,ECOG score,parts of the primary tumor metastasis and recurrence that there were no statistical significantly differences between the clinical characteristics（P〈0.05）.Conclusion UGT1A1＊28gene wild type TA（6）/TA（6）are most common,miscellaneous collection type TA（6）/TA（7）followed by;Delayed diarrhea occurred and dose strength no obviously correlation,UGT1A1＊28gene polymorphism is dangerous factors of diarrhea,TA（6）/TA（7）type gene patients delayed diarrhea occurred rate is increased.Neutropenia occurred and dose strength are related.
出处
《贵州医药》
CAS
2015年第7期586-588,共3页
Guizhou Medical Journal
作者简介
通信作者，E—mail：zenwo@qq．com.
